This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00127179
First received: August 3, 2005
Last updated: April 5, 2017
Last verified: April 2017
August 3, 2005
April 5, 2017
January 1, 2004
July 1, 2005   (Final data collection date for primary outcome measure)
Change from baseline in the International Prostate Symptom Score
Not Provided
Complete list of historical versions of study NCT00127179 on ClinicalTrials.gov Archive Site
  • Change from baseline in QOL - index
  • Change from baseline in maximum urinary flow rate, %
  • Change from baseline in Prostate volume
Not Provided
Not Provided
Not Provided
 
A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)
MK0906 Phase III Double-Blind Comparative Study - Benign Prostate Hyperplasia
The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with benign prostatic hyperplasia.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Benign Prostatic Hyperplasia
  • Drug: MK0906, finasteride / Duration of Treatment: 48 weeks
  • Drug: Comparator: placebo / Duration of Treatment: 48 weeks
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
600
July 25, 2005
July 1, 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with benign prostatic hyperplasia

Exclusion Criteria:

  • Patients who are suspected to be suffering from prostatic cancer
Sexes Eligible for Study: Male
50 Years to 79 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
Japan
 
NCT00127179
0906-140
MK0906-140
2005_042
Not Provided
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP